Abstract
AbstractA method for the “carrier‐added” synthesis of [13N]cisplatin is described. Yields were ∼1–4 mCi from 20–40 mCi of [13N]ammonia with a total synthesis time of 19–28 minutes. The product was ∼96% radiochemically pure as judged by HPLC analysis and had a specific activity of ∼100 mCi/mmole in 1.0 ml of saline. [13N]Cisplatin was administered intraperitoneally to mice. Of the tissues investigated, concentration of label was highest in kidneys. At 10 min, considerable label in the blood, liver, and kidney was in a form other than cisplatin. However, no evidence was obtained that [13N]ammonia was released from [13N]cisplatin in vivo. [13N]Cisplatin may be used to assess drug delivery to primary and metastatic brain tumors in patients receiving intravenous or intraarterial cisplatin chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
